drugset / Trial / NCT02822222

Safety Study of RMJH-111b to Treat Essential Hypertension

NCT02822222 ↗

Phase 1/2 Completed 22 enrolled RMJ Holdings, LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension. The study also measured the amount of magnesium in the blood and urine before and after RMJH-111b administration to evaluate what the body does to RMJH-111b (pharmacokinetics).

Timeline

Start
2016-06-10
Primary completion
2016-07-07
Completion
2016-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium citrate, tribasic anhydrous Unknown 440 mg Oral